Search results
Results from the WOW.Com Content Network
For premium support please call: 800-290-4726 more ways to reach us
VIVUS' (NAS: VVUS) stock was down 25% for November, though still up 15% for the year. Its drug Qsymia is the first obesity drug to be approved and reach the market in more than a decade, but its ...
VIVUS Inc. (NASDAQ: VVUS) reported a quarterly loss of $0.56 per share on Monday, but this was not an earnings story. VIVUS remains a developing story about its obesity drug Qsymia. Its revenue ...
VIVUS (NAS: VVUS) may have beaten its rival Arena Pharmaceuticals (NAS: ARNA) in getting an obesity drug on the market first, but its shares plunged almost 20% this morning after reporting ...
The pieces of the puzzle are starting to fall into place for VIVUS (NASDAQ: VVUS) and its potential blockbuster anti-obesity drug, Qsymia. The drug, which was approved by the Food and Drug ...
We are initiating coverage of VIVUS, Inc. (VVUS) with a $10.00 price target based on our revenue forecasts for approved products. In addition to a portfolio of weight loss, exocrine pancreatic ...
When considering any stock for your portfolio, don't be swayed by just the positives. ... VVUS) , a biotechnology. Skip to main content. 24/7 Help. For premium support please call: 800-290-4726 ...
VIVUS (NAS: VVUS) investors may have breathed a sigh of relief after the company's obesity drug, Qsymia, gained approval from the Food and Drug Administration this summer -- but passing this ...